natgillin/translations-raw huggingface dataset:
Irbesartan and hydrochlorothiazide (at doses up to 300 mg irbesartan/25 mg hydrochlorothiazide) have been safely administered with other antihypertensive agents including calcium channel blockers and beta-adrenergic blockers.
pri odmerkih do 300 mg irbesartana/25 mg hidroklorotazida, je pri bolnikih, ki dobivajo še druge antihipertenzive, tudi blokatorje kalcijevih kanalčkov in adrenergičnih receptorjev beta, varna.
Therefore, the combination of lithium and Irbesartan Hydrochlorothiazide Zentiva is not recommended (see section 4.4).
Sočasna uporaba litija in zdravila Irbesartan Hydrochlorothiazide Zentiva zato ni priporočljiva (glejte poglavje 4.4).
Preparations containing lithium should not be taken with Irbesartan Hydrochlorothiazide Zentiva without close supervision by your doctor.
Zdravila, ki vsebujejo litij, smete z zdravilom Irbesartan Hydrochlorothiazide Zentiva jemati le pod strogim zdravniškim nadzorom.
No dosage adjustment is necessary in patients with renal impairment whose renal creatinine clearance is ≥30 ml/min (see sections 4.3 and 4.4).
Pri bolnikih z ledvično okvaro, pri katerih je ledvični očistek kreatinina ≥ 30 ml/min, prilagoditev odmerka ni potrebna (glejte poglavji 4.3 in 4.4).
Red and yellow ferric oxides Carnauba wax
rdeči in rumeni železov oksid karnauba vosek
Irbesartan Hydrochlorothiazide Zentiva is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Irbesartan Hydrochlorothiazide Zentiva ne smete jemati, če ste noseči dlje kot 3 mesece, saj lahko zdravilo v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of Irbesartan Hydrochlorothiazide Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m²) (see sections 4.5 and 5.1).
Sočasna uporaba zdravila Irbesartan Hydrochlorothiazide Zentiva in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (hitrost glomerularne filtracije < 60 ml/min/1,73 m2) (glejte poglavji 4.5 in 5.1).
Irbesartan Hydrochlorothiazide Zentiva is unlikely to affect your ability to drive or use machines.
Hydrochlorothiazide Zentiva vplivalo na sposobnost vožnje in upravljanja s stroji.
Irbesartan Hydrochlorothiazide Zentiva is not indicated in patients with severe hepatic impairment.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva ni primerno za bolnike s hudo jetrno okvaro.
blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).
(encim kreatin-kinaza), ali zvišanje vrednosti snovi, ki so merilo delovanja ledvic (dušik sečnine v krvi, kreatinin).
Red and black ferric oxides Carnauba wax
rdeči in črni železov oksid karnauba vosek
Uncommon: Not known:
Presnovne in prehranske motnje: Neznana:
However, in patients with mild to moderate renal impairment (creatinine clearance ≥30 ml/min but <60 ml/min) this fixed dose combination should be administered with caution.
Bolnikom z ledvično okvaro, pri katerih je ledvični očistek ≥ 30 ml/min, odmerka zdravila ni treba prilagajati, kljub temu pa je treba tistim z blago ali zmerno ledvično okvaro (očistek kreatinina ≥ 30 ml/min, toda < 60 ml/min) dajati kombinirano zdravilo zelo previdno.
increases in blood urea nitrogen (BUN), creatinine and creatine kinase
zvišanje vrednosti dušika sečnine v krvi (BUN),
A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).
Razmerje med kumulativnim odmerkom in odzivom so dokazali s tem, da se je prilagojeni OR z 2,1 (95-odstotni IZ: 1,7-2,6), zvišal na 3,9 (3,0-4,9) pri velikih odmerkih (~
Uncommon side effects ( may affect up to 1 in 100 people): diarrhoea low blood pressure fainting heart rate increased flushing swelling sexual dysfunction (problems with sexual performance) blood tests may show lowered levels of potassium and sodium in your blood.
driska nizek krvni tlak omedlevica hiter srčni utrip zardevanje otekline spolne motnje (težave pri spolnih odnosih) krvne preiskave lahko pokažejo znižane vrednosti kalija in natrija v krvi.
If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Irbesartan Hydrochlorothiazide Zentiva” and “Warnings and precautions”).
Če jemljete zaviralec ACE ali aliskiren (glejte tudi informacije pod naslovoma "Ne jemljite zdravila
Due to the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide Zentiva, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.
lahko hidroklorotiazid, ki ga vsebuje zdravilo Irbesartan Hydrochlorothiazide Zentiva, povzroči omotico v stoječem položaju, še posebej po vstajanju iz sedečega položaja.
Your doctor will instruct you how to switch from the previous treatment to Irbesartan Hydrochlorothiazide Zentiva.
Povedal vam bo tudi, kako prenehati jemati dosedanje zdravilo in kako začeti zdravljenje z zdravilom Irbesartan Hydrochlorothiazide Zentiva.
Children should not take Irbesartan Hydrochlorothiazide Zentiva Irbesartan Hydrochlorothiazide Zentiva should not be given to children under 18 years of age.
Otroci, mlajši od 18 let, zdravila Irbesartan Hydrochlorothiazide Zentiva ne smejo jemati.
Other medicines and Irbesartan Hydrochlorothiazide Zentiva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Due to the hydrochlorothiazide component, Irbesartan Hydrochlorothiazide Zentiva is not recommended for patients with severe renal dysfunction (creatinine clearance <30 ml/min).
Zdravilo Irbesartan Hydrochlorothiazide Zentiva vsebuje hidroklorotiazid, zato za bolnike s hudo motenim delovanjem ledvic (očistek kreatinina < 30 ml/min) ni primeren.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) andVA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Dvojna blokada sistema renin-angiotenzin-aldosteron (RAAS) Uporabo zaviralca ACE v kombinaciji z blokatorjem receptorjev angiotenzina II so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) in VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes).
if you get excessive vomiting or diarrhoea if you suffer from kidney problems or have a kidney transplant if you suffer from heart problems if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
če začnete prekomerno bruhati ali dobite hudo drisko če imate težave z ledvicami ali presajeno ledvico če imate težave s srcem če imate težave z jetri če imate sladkorno bolezen če imate eritematozni lupus (znan tudi kot lupus ali sistemski eritematozni lupus) če imate primarni aldosteronizem (stanje, povezano s čezmernim izločanjem hormona aldosterona, kar povzroči zastajanje natrija in posledično zvišanje krvnega tlaka)
Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is recommended when Irbesartan Hydrochlorothiazide Zentiva is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).
Zdravila, na katera vpliva serumska koncentracija kalija: med hkratnim zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide Zentiva in drugimi zdravili, na katerih delovanje vpliva serumska koncentracija kalija (npr. z digitalisovimi glikozidi, antiaritmiki), je priporočeno redno preverjanje kalija v serumu.
No specific information is available on the treatment of overdose with Irbesartan Hydrochlorothiazide Zentiva.
O zdravljenju posledic prevelikega odmerjanja zdravila Irbesartan Hydrochlorothiazide Zentiva ni specifičnih podatkov.
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Irbesartan Hydrochlorothiazide Zentiva.
Dodatni podatki o posameznih učinkovinah: poleg zgoraj naštetih neželenih učinkov, ki se lahko pojavijo med uporabo kombiniranega zdravila, se utegnejo med jemanjem zdravila Irbesartan
chest pain
Pet Sob Ned
Cardiovascular death and stroke were both numerically more frequent in the aliskiren group that in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.
Tudi resni interesantni neželeni učinki (hiperkaliemija, hipotenzija in disfunkcija ledvic) so bili v skupini, ki je prejemala aliskiren, pogostejši kot v skupini, ki je prejemala placebo.
How to take Irbesartan Hydrochlorothiazide Zentiva
Kako jemati zdravilo Irbesartan Hydrochlorothiazide Zentiva
Food does not affect the bioavailability of Irbesartan Hydrochlorothiazide Zentiva.
Sočasno uživanje hrane na biološko uporabnost zdravila Irbesartan Hydrochlorothiazide Zentiva ne vpliva.
Side effects reported in clinical studies for patients treated with Irbesartan Hydrochlorothiazide Zentiva were:
Med kliničnimi študijami so pri bolnikih, ki so se zdravili z zdravilom Irbesartan Hydrochlorothiazide Zentiva, poročali o naslednjih neželenih učinkih:
Irbesartan AUC and Cmax values were also somewhat greater in older subjects (≥ 65 years) than those of young subjects (18-40 years).
(≥ 65 let) nekoliko večji kot pri mlajših (18 do 40 let).
The frequency of the side effects listed below is defined using the following convention: Common: may affect up to 1 in 10 people
V nadaljevanju so neželeni učinki navedeni po pogostnosti v skladu z naslednjim dogovorom: pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov občasni: pojavijo se lahko pri največ 1 od 100 bolnikov
Irbesartan Hydrochlorothiazide Zentiva contains lactose.
Zdravilo Irbesartan Hydrochlorothiazide Zentiva vsebuje laktozo.
You should also tell your doctor: if you are on a low-salt diet if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Irbesartan Hydrochlorothiazide Zentiva) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking Irbesartan Hydrochlorothiazide Zentiva.
Svojemu zdravniku morate tudi povedati: če imate dieto z zmanjšanim vnosom soli če imate znake, kot so nenormalna žeja, suha usta, splošna oslabelost, zaspanost, bolečine ali krči v mišicah, siljenje na bruhanje, bruhanje ali nenormalno hiter srčni utrip, ki so lahko posledica prevelikega učinka hidroklorotiazida (ki ga vsebuje zdravilo Irbesartan
Not applicable.
niso ugotavljali.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Uporabo zaviralca ACE v kombinaciji z blokatorjem receptorjev angiotenzina II so raziskali v dveh velikih randomiziranih, kontroliranih preskušanjih: ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) in VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes).
You may need to have blood checks if you take: potassium supplements salt substitutes containing potassium potassium sparing medicines or other diuretics (water tablets) some laxatives medicines for the treatment of gout therapeutic vitamin D supplements medicines to control heart rhythm medicines for diabetes (oral agents or insulins) carbamazepine (a medicine for the treatment of epilepsy).
pripravke s kalijem nadomestke soli, ki vsebujejo kalij zdravila, ki varčujejo s kalijem ali druge diuretike (tablete za odvajanje vode) nekatera odvajala zdravila za zdravljenje protina dodatke vitamina D
The two active ingredients in Irbesartan Hydrochlorothiazide Zentiva work together to lower blood pressure further than if either was given alone.
Zdravilni učinkovini v zdravilu Irbesartan Hydrochlorothiazide Zentiva znižujeta krvni tlak, in to še bolj kot če bi jemali vsako učinkovino posebej.
Irbesartan Hydrochlorothiazide Zentiva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Mehanizem delovanja Zdravilo Irbesartan Hydrochlorothiazide Zentiva je kombinacija irbesartana, antagonista angiotenzina
If you take more Irbesartan Hydrochlorothiazide Zentiva than you should If you accidentally take too many tablets, contact your doctor immediately.
Če ste pomotoma vzeli preveč tablet, se nemudoma posvetujte s svojim zdravnikom.
An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry.
Nemelanomski kožni rak Dve epidemiološki študiji, izvedeni na podlagi podatkov registra raka za Dansko, sta pokazali, da zaradi izpostavljenosti povečanemu kumulativnemu odmerku hidroklorotiazida obstaja povečano tveganje za razvoj nemelanomskega kožnega raka (bazalnoceličnega karcinoma in ploščatoceličnega karcinoma).
Therefore, the use of Irbesartan Hydrochlorothiazide Zentiva is not recommended.
Hydrochlorothiazide Zentiva pri njih zato ni priporočena.
Rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.
koprivnica) in o lokaliziranih oteklinah obraza, ustnic in/ali jezika.
When measured by ambulatory blood pressure monitoring, the trough to peak effects of Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg were 100%.
Med 24-urnim merjenjem krvnega tlaka pri bolnikih, ki so prejemali zdravilo Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg, je bilo razmerje med najmanjšim in največjim učinkom 100%.
aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia
aplastična anemija, zavora delovanja kostnega mozga, nevtropenija/agranulocitoza,
Titanium dioxide Macrogol 3000
Filmska obloga: laktoza monohidrat hipromeloza titanov dioksid makrogol 3000
Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide Zentiva is unlikely to affect the ability to drive and use machines.
Možnost, da bi zdravilo Irbesartan Hydrochlorothiazide Zentiva vplivalo na sposobnost za upravljanje vozil in strojev je majhna.
Irbesartan/hydrochlorothiazide combination:
Irbesartan/hidroklorotiazid:
How to store Irbesartan Hydrochlorothiazide Zentiva
Shranjevanje zdravila Irbesartan Hydrochlorothiazide Zentiva
(It is also better to avoid Irbesartan Hydrochlorothiazide Zentiva in early pregnancy - see pregnancy section) if you have severe liver or kidney problems if you have difficulty in producing urine if your doctor determines that you have persistently high calcium or low potassium levels in your blood if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.
če imate hudo okvaro jeter ali ledvic če imate težave z odvajanjem seča če je zdravnik ugotovil, da imate stalno zvečano koncentracijo kalcija ali zmanjšano koncentracijo kalija v krvi če imate sladkorno bolezen ali okvarjeno delovanje ledvic in se zdravite z zdravilom za znižanje krvnega tlaka, ki vsebuje aliskiren.
No dosage adjustment of Irbesartan Hydrochlorothiazide Zentiva is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Pri bolnikih z blago do zmerno jetrno okvaro prilagoditev odmerka ni potrebna (glejte poglavje 4.3).
Each film-coated tablet contains 38.5 mg of lactose (as lactose monohydrate).
Ena filmsko obložena tableta vsebuje 38,5 mg laktoze (v obliki laktoze monohidrata).
Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid.
Zdravila za zdravljenje protina: hidroklorotiazid lahko zveča serumsko koncentracijo sečne kisline,
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg tablete so na voljo v pretisnih omotih s 14, 28, 56 ali 98 tabletami.
The use of Irbesartan Hydrochlorothiazide Zentiva during breast feeding is not recommended.
Uporaba zdravila Irbesartan Hydrochlorothiazide Zentiva v zgodnjem obdobju nosečnosti ni priporočljiva.
There is no clinical experience with Irbesartan Hydrochlorothiazide Zentiva in patients with hepatic impairment.
Hydrochlorothiazide Zentiva pri bolnikih z jetrno okvaro ni.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg tablete so na voljo v pretisnih omotih s 14, 28, 56 ali 98 tabletami.
Anaphylactic reaction including anaphylactic shock Table 3: Adverse reactions reported with the use of hydrochlorothiazide alone
Tabela 3: Neželeni učinki, o katerih so poročali pri uporabi hidroklorotiazida samega Preiskave:
Table 2: Adverse reactions reported with the use of irbesartan alone
Tabela 2: Neželeni učinki, o katerih so poročali pri uporabi irbesartana samega Bolezni krvi in limfatičnega sistema:
Microcrystalline cellulose Croscarmellose sodium Lactose monohydrate Magnesium stearate Colloidal hydrated silica Pregelatinised maize starch Red and yellow ferric oxides (E172)
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi mikrokristalna celuloza premreženi natrijev karmelozat laktoza monohidrat magnezijev stearat hidratirani koloidni silicijev dioksid predgelirani koruzni škrob rdeči in rumeni železov oksid (E172)
A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force-titrated (before assessing the response to the lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively.
Po enem tednu zdravljenja so odmerek sistematično povečali (pred ovrednotenjem odziva na nižji odmerek) na irbesartan/hidroklorotiazid 300 mg/25 mg oziroma irbesartan 300 mg.
Side effects reported since the launch of Irbesartan Hydrochlorothiazide Zentiva Some undesirable effects have been reported since marketing of Irbesartan Hydrochlorothiazide Zentiva.
Zentiva na tržišče Po prihodu zdravila Irbesartan Hydrochlorothiazide Zentiva na tržišče so poročali še o nekaterih drugih neželenih učinkih.
• stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
pri nekaj podganah, ki so v študiji toksičnosti 6 mesecev dobivale po 90 mg irbesartana na kg/dan in 90 mg hidroklorotiazida na kg/dan ter kombinacijo irbesartana in hidroklorotiazida (10 mg/10 mg/kg/dan), so opazili spremembo barve želodca, razjede in fokalno nekrozo želodčne sluznice; teh lezij pri opicah ni bilo;
anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria
vnetje kožnih žil ali mezgovnic), reakcije, podobne kožnemu eritematoznemu lupusu, reaktivacija kožnega eritematoznega lupusa,
• decreases in serum potassium due to hydrochlorothiazide and partly prevented when hydrochlorothiazide was given in combination with irbesartan.
znižanje kalija v serumu med uporabo hidroklorotiazida, ki je bilo med kombiniranim dajanjem z irbesartanom manj izrazito.
The trough to peak effects measured by cuff during office visits were 68% and 76% for Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg and Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg, respectively.
Pri merjenju z manšeto v ambulanti je bilo pri bolnikih, ki so jemali zdravilo Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg, to razmerje 68%, pri tistih, ki so dobivali zdravilo Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg, pa
Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed.
Nemelanomski kožni rak: Na podlagi obstoječih podatkov epidemioloških študij so ugotovili, da obstaja razmerje med kumulativnim odmerkom hidroklorotiazida in nemelanomskim kožnim rakom.
Thiazide diuretic-associated azotemia may occur in patients with impaired renal function.
Pri bolnikih z okvarjeno ledvično funkcijo se lahko zaradi jemanja tiazidnih diuretikov pojavi azotemija.
Each film-coated tablet of Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide.
Zentiva 300 mg/25 mg filmsko obložena tableta vsebuje 300 mg irbesartana in 25 mg hidroklorotiazida.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
EU/1/06/377/006 - 14 tablets EU/1/06/377/007 - 28 tablets EU/1/06/377/008 - 56 tablets EU/1/06/377/009 - 56 x 1 tablets EU/1/06/377/010 - 98 tablets
EU/1/06/377/009 - 56 x 1 tableta EU/1/06/377/010 - 98 tablet
Each film-coated tablet of Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Ena Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg filmsko obložena tableta vsebuje 150 mg irbesartana in 12,5 mg hidroklorotiazida.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg filmsko obložene tablete so na voljo v pretisnih omotih s 14, 28, 30, 56, 84, 90 ali 98 filmsko obloženimi tabletami.
Because no information is available regarding the use of Irbesartan Hydrochlorothiazide Zentiva during breast-feeding, Irbesartan Hydrochlorothiazide Zentiva is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Podatkov o uporabi zdravila Irbesartan Hydrochlorothiazide Zentiva med dojenjem ni na voljo, zato uporaba zdravila Irbesartan Hydrochlorothiazide Zentiva med dojenjem ni priporočljiva.